CA2662798A1 - Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications - Google Patents

Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications Download PDF

Info

Publication number
CA2662798A1
CA2662798A1 CA002662798A CA2662798A CA2662798A1 CA 2662798 A1 CA2662798 A1 CA 2662798A1 CA 002662798 A CA002662798 A CA 002662798A CA 2662798 A CA2662798 A CA 2662798A CA 2662798 A1 CA2662798 A1 CA 2662798A1
Authority
CA
Canada
Prior art keywords
peptide
mhc
cells
specific
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002662798A
Other languages
English (en)
Inventor
Jon A. Weidanz
Vaughan Wittman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RECEPTOR LOGIC Ltd
Original Assignee
Receptor Logic, Ltd.
Jon A. Weidanz
Vaughan Wittman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Logic, Ltd., Jon A. Weidanz, Vaughan Wittman filed Critical Receptor Logic, Ltd.
Publication of CA2662798A1 publication Critical patent/CA2662798A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002662798A 2005-09-07 2006-09-07 Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications Abandoned CA2662798A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US71462105P 2005-09-07 2005-09-07
US60/714,621 2005-09-07
US75154205P 2005-12-19 2005-12-19
US60/751,542 2005-12-19
US75273705P 2005-12-20 2005-12-20
US60/752,737 2005-12-20
US83827606P 2006-08-17 2006-08-17
US60/838,276 2006-08-17
PCT/US2006/034547 WO2007030451A2 (fr) 2005-09-07 2006-09-07 Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications

Publications (1)

Publication Number Publication Date
CA2662798A1 true CA2662798A1 (fr) 2007-03-15

Family

ID=37836380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662798A Abandoned CA2662798A1 (fr) 2005-09-07 2006-09-07 Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications

Country Status (5)

Country Link
EP (1) EP1933864A4 (fr)
AU (1) AU2006289683A1 (fr)
CA (1) CA2662798A1 (fr)
IL (1) IL190014A0 (fr)
WO (1) WO2007030451A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143104A2 (fr) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations
WO2009108372A2 (fr) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL154000A0 (en) * 2000-08-14 2003-07-31 Akzo Nobel Nv Use of antibodies against specific mhc-peptide complexes
WO2002046416A2 (fr) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Immunogenes induisant une reponse des lymphocytes t cytotoxiques pour la prevention, le traitement et le diagnostic de cancers
CA2476625A1 (fr) * 2002-02-20 2003-08-28 Dyax Corp. Ligands de liaison au complexe mhc-peptide
FR2839452A1 (fr) * 2002-05-07 2003-11-14 Pf Medicament Utilisation de peptide derive de la sous-unite beta de l'hcg pour generer une reponse de type ctl antitumorale
WO2004101607A2 (fr) * 2003-05-13 2004-11-25 Hildebrand William H Representation cartographique comparative de ligands a partir de cellules positives de classe i du cmh
EP1773383B1 (fr) * 2004-05-27 2012-09-12 Jon A. Weidanz Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation

Also Published As

Publication number Publication date
EP1933864A2 (fr) 2008-06-25
WO2007030451A2 (fr) 2007-03-15
AU2006289683A1 (en) 2007-03-15
IL190014A0 (en) 2008-08-07
WO2007030451A3 (fr) 2009-04-16
EP1933864A4 (fr) 2009-12-16

Similar Documents

Publication Publication Date Title
CA2567814C (fr) Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
US20090226474A1 (en) Antibodies as T cell receptor mimics, methods of production and uses thereof
CA2656583A1 (fr) Anticorps utiles en tant qu'analogues de recepteur des lymphocytes t, leurs procedes de production et leurs utilisations
US20110293623A1 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
US20140065708A1 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
AU2008234530B2 (en) Antibodies, methods and kits for diagnosing and treating melanoma
JP2022109915A (ja) Ｃｄ８０バリアント免疫調節タンパク質およびその使用
EP1763365B1 (fr) Anticorps pour apoptose selective de cellules
KR20190140924A (ko) Cd80 변이체 면역조절 단백질 및 그의 용도
JP2023055821A (ja) バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
US20140141455A1 (en) Methods of assaying vaccine potency
US20180179283A1 (en) T cell receptor like antibodies having fine specificity
US20090075304A1 (en) Methods of assaying vaccine potency
CA2662798A1 (fr) Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications
EP2262834A2 (fr) Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d utilisation
JP2020533970A (ja) 抗ｃｄ３抗体とその作製及び使用方法
US20160017031A1 (en) T cell receptor mimic rl9a
US20230046744A1 (en) Methods and means for attracting immune effector cells to tumor cells
US11999793B2 (en) Therapeutic anti-CD9 antibody
US20220017636A1 (en) Mageb2 binding constructs
Miller Use of T cell receptor-like antibody fragments for imaging and immunotherapy

Legal Events

Date Code Title Description
FZDE Discontinued